Skip to Navigation Skip to Search Skip to Content
Search All Centers

Myeloma News From ASH 2018: Groundbreaking Data for the Future of Myeloma

Read Transcript Download/Print Transcript

Published on December 18, 2018

On-location in San Diego, at the 60th annual American Society of Hematology (ASH) meeting, leading myeloma expert Dr. Faith Davies, from The UAMS Myeloma Institute, joins Patient Power to share recent breakthroughs in multiple myeloma treatment research presented at the conference. During this interview, Dr. Davies explores cutting-edge combination therapies, advances in treating patients in the maintenance and relapse setting, and new avenues to help manage toxicities and improve quality of life. Watch now to find out more.

Featuring

You might also like

Transcript | Myeloma News From ASH 2018: Groundbreaking Data for the Future of Myeloma

Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, contributors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. That's how you’ll get care that's most appropriate for you.

Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, contributors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. That’s how you’ll get care that’s most appropriate for you.

Lee Swanson:

We've been hearing about new combinations that we can maybe use for newly diagnosed patients, and how that by combining either maybe three drugs or four drugs we can get a tolerable regime, but also one that induces good responses.   

And then we've been hearing a lot about new maintenance drugs.  So previously many patients had been receiving lenalidomide (Revlimid) maintenance, but now there's an oral proteasome inhibitor which has shown to be good for myeloma as well.  

And then in the relapsed setting lots of new drugs have been discussed.  Many of them I think are going to be groundbreaking, such as the CAR-T cells, but there have also been drugs that maybe we can use in specific groups of patients which seem to be really effective.  

Many of the others are still in the clinical trial phase, and so if patients want to get involved with some of those, again they need to chat with their doctor and get connected up with a site that may have some of those drugs.  But I don't think anything we've spoken about over the last few days is years away.  It's all in the very near future, which is exciting.  

One of the studies that was introduced today actually for patients who are maybe slightly older and which maybe are not able to use transplantation, with the drugs that those patients have been receiving, including antibodies, their survivals now are getting up to what we might expect for the younger patients who are having transplantation.  

I guess one of the groups that we have been hearing about that we still need a lot of work in there is the high-risk patients, and that's still very challenging, and that's really come across in quite a lot of the talks as well.  So that's an area that we need to concentrate on.  We're very hopeful that the new treatments we're going to use are going to be good for those patients, but it's still an area of unmet need. 

Lee Swanson:

Well, you're right. There is a lot going on here this week, isn't there?  

Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, contributors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. That’s how you’ll get care that’s most appropriate for you.